drugset / Trial / NCT05703425

The Effect of Sulfasalazine on CRH Levels in Pregnant Women

NCT05703425

Phase 2 Recruiting 50 enrolled Rutgers, The State University of New Jersey
RandomizedSequentialOpen-labelTreatment

Summary

The goal of this randomized clinical trial is to assess sulfasalazine as a potential treatment to prevent recurrent preterm birth. The main questions it aims to answer are: * Does sulfasalazine down regulate corticotropin releasing hormone (CRH) levels in pregnant persons with a prior history of preterm birth? * Does sulfasalazine reduce the incidence of recurrent preterm birth in pregnant persons given drug vs. controls? Consenting participants will be randomized to receive sulfasalazine or to a control group and will undergo serial blood draws to assess plasma CRH levels.

Timeline

Start
2023-03-01
Primary completion
2028-01-31
Completion
2028-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Sulfasalazine Small molecule 1000 mg Oral

Indications

No indication recorded.